Resistance-associated mutations in the human immunodeficiency virus type 1 subtype C protease gene from treated and untreated patients in the United Kingdom

Journal of Clinical Microbiology

Volumn 39, Issue 7, 2001, Pages 2652-2654

  Cane, P A ^a   De Ruiter, A ^a   Rice, P ^a   Wiselka, M ^a   Fox, R ^a   Pillay, D ^a  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; INDINAVIR; LOPINAVIR; NELFINAVIR; PROTEINASE; PROTEINASE C; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ARTICLE; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; NONHUMAN; PRIORITY JOURNAL; SEQUENCE ANALYSIS; UNITED KINGDOM; VIRUS MUTATION;

DISEASES IN TWINS; DRUG RESISTANCE, MICROBIAL; GREAT BRITAIN; HIV INFECTIONS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INFANT; MUTATION; TWINS;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; RNA VIRUSES;

EID: 0034952105     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.39.7.2652-2654.2001     Document Type: Article

References (16)

1. At least five HIV-1 sequence subtypes (A, B, C, D, A/E) occur in England
2. Recombinant strains of HIV type 1 in the UK
3. High frequency of non-B subtypes in newly diagnosed HIV-1 infections in Switzerland
4. Antiretroviral drug resistance testing in adult HIV-1 infection: Recommendations of an International AIDS Society-USA panel
5. The emerging genetic diversity of HIV. The importance of global surveillance for diagnostics, research, and prevention
6. Extensive polymorphisms observed in HIV-1 clade B protease gene using high-density oligonucleotide arrays
7. Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir
8. Protease sequences from HIV-1 group M subtypes A-H reveal distinct amino acid mutation patterns associated with protease resistance in protease inhibitor-naïve individuals worldwide
9. Detection of drug resistance associated mutations in HIV primary infection within the UK
10. Correlation of response to treatment and HIV genotypic changes during phase III trials with saquinavir and reverse transcriptase inhibitor combination therapy
11. Sequence and drug susceptibility of subtype C protease from human immunodeficiency virus type 1 seroconverters in Zimbabwe
12. Human immunodeficiency virus reverse transcriptase and protease sequence database
13. Genetic diversity of protease and reverse transcriptase sequences in non-subtype-B human immunodeficiency virus type 1 stains: Evidence of many minor drug resistance mutations in treatment-naíve patients
14. Presence of human immunodeficiency virus (HIV) type 1, group M, non-B subtypes, Bronx, New York: A sentinel site for monitoring HIV genetic diversity in the United States
15. Resistance mutations in protease and reverse transcriptase genes of human immunodeficiency virus type 1 isolates from patients with combination antiretroviral therapy failure
16. Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites